The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

Rheumatology

Volumn 50, Issue 7, 2011, Pages 1341-1342

  Galloway, James B ^a   Hyrich, Kimme L ^a   Mercer, Louise K ^a   Dixon, William G ^a   Watson, Kath D ^a   Lunt, Mark ^a   Symmons, Deborah P M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT ONSET STILL DISEASE; BIOLOGICAL THERAPY; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; INFECTION; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

AGE DISTRIBUTION; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INCIDENCE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SOCIETIES, MEDICAL; SURVIVAL RATE;

EID: 79959461674     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker146     Document Type: Letter

References (7)

1. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009(1):CD005121.
2. Lequerre T, Quartier P, Rosellini D et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-8.
3. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803.
4. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-26.
5. Chevalier X, Goupille P, Beaulieu AD et al. Intra-articular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebocontrolled study. Arthritis Rheum 2009;61:344-52.
6. Hyrich KL, Watson KD, Isenberg DA, Symmons DP. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology 2008;47:1441-3.
7. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50: 124-31.